MedTrace Logo

A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

NCT07735546 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-17

No results posted yet for this study

Summary

This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.

Conditions

  • Multiple Myeloma in Relapse
  • Multiple Myeloma (MM)

Interventions

GENETIC

UB-VV500

UB-VV500 is a gene therapy that generates CAR T cells that target both B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) in the body.

DRUG

Rapamycin (sirolimus)

Rapamycin is a drug approved by the FDA for indications unrelated to cancer.

Sponsors & Collaborators

  • Umoja Biopharma

    lead INDUSTRY

Principal Investigators

  • Luke Walker, MD · Umoja Biopharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2029-12-31
Completion
2029-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07735546 on ClinicalTrials.gov